Safety of intranasal Bevacizumab (avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis

Laryngoscope

Volumn 121, Issue 3, 2011, Pages 644-646

  Chen IV, Sonia ^a   Karnezis, Tom ^a   Davidson, Terence M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Avastin; Bevacizumab; Epistaxis; hereditary hemorrhagic telangiectasia; Osler Weber Rendu

Indexed keywords

BEVACIZUMAB; NOSE SPRAY;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CONTROLLED CLINICAL TRIAL; EPISTAXIS; FEMALE; HEALTH SURVEY; HUMAN; INTERVIEW; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; MUCOSAL ADMINISTRATION; NOSE SEPTUM; NOSE SEPTUM PERFORATION; PATIENT SAFETY; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE; SUBMUCOSA;

ADMINISTRATION, INTRANASAL; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; EPISTAXIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; LASER COAGULATION; LASERS, SOLID-STATE; MALE; MIDDLE AGED; NASAL MUCOSA; NASAL SEPTUM; NASAL SPRAYS; RETROSPECTIVE STUDIES; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; YOUNG ADULT;

EID: 79951890796     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.21345     Document Type: Article

References (10)

1. Guttmacher AE, Marchuk DA, White RI., Hereditary hemorrhagic telangiectasia. N Engl J Med 1995; 333: 918-924.
2. United States. Cong. Senate. Committee on Health, Education, Labor and Pension. S. Res. 508. 111th Cong. 2nd sess. Washington, DC: GPO; 2010.
3. Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA., An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope 2010; 120: 838-843.
4. ten Dijke P, Arthur HM., Extracellular TGFbetal signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007; 8: 857-869. (Pubitemid 47622560)
5. Sadick H, Riedel F, Naim R, Goessler U, Hormann K, Hafner M, Lux A., Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor β1 as well as high ALK1 tissue expression. Haematologica 2005; 90: 818-828.
6. Davidson TM, Olitsky SE, Wei JL,. Hereditary hemorrhagic telangiectasia/avastin. Laryngoscope 2010; 120: 432.
7. Simonds J, Miller F, Mandel J, Davidson TM., The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2009; 119: 988-992.
8. Bose P, Holter JL, Selby GB., Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009; 360: 2143-2144.
9. Genentech Inc. (2009, July). Retrieved April 14, 2010, from Avastin prescribing information http://www.gene.com/gene/products/information/oncology/ avastin/
10. Lynch SS, Cheng CM., Bevacizumab for neovascular ocular disease. Ann Pharmacother 2007; 41: 614-625.